博士，研究员，博士生/后导师，国家高层次青年人才、四川省高层次青年人才，华西医院临床药学研究所副所长，华西医院药剂科临床药学室负责人，比利时鲁汶大学兼职教授（scientific collaborator）/博士生导师。任四川省医学会临床药学专委会青年副主委等。博士毕业于比利时鲁汶大学鲁汶药物研究所，曾任英国剑桥大学代谢科学研究所、鲁汶大学鲁汶药物研究所博士后、项目研究员。主要从事重大慢病的防治研究，聚焦代谢性疾病等。相关研究成果以通讯作者/第一作者在国际权威学术期刊Science Advances、Gut、ACS Nano、Bioactive Materials、Advanced Drug Delivery Reviews等发表。主要科研成果申请国际PCT专利，并获欧洲学术委员会临床专项转化基金的支持。多次获邀在国际知名学术会议进行学术报告。主要科研项目包括国家自然科学基金优秀青年科学基金（海外）、国家科技创新2030“四大慢病”重大专项课题、国家自然科学基金面上项目、比利时国家科学基金FNRS-ASP基金、比利时国家科学基金FNRS-CR基金等。获国际控释协会（CRS）口服递送分会青年科学家奖、多项欧洲学术委员会奖励、欧洲药剂学2020最杰出博士文论奖（唯一）、比利时交叉学科2020最佳博士论文奖等。
1. 四川省医学会临床药学专业委员会青年委员会副主任委员等
2. Pharmaceutics，客座编辑，IF=5.4；四川大学学报（医学版）青年编委等
3.长期担任特邀审稿人为Journal of Hematology & Oncology, Advanced Functional Materials, Journal of Controlled Release, Small, Acta Biomaterialia, Molecular Therapy, Acta Pharmaceutica Sinica B, Journal of Nanobiotechnology, Advanced NanoBiomed Research, ACS Applied Materials & Interfaces等高水平期刊杂志进行同行评审。
主要科研项目：
1. 国家科技创新2030“四大慢病”重大专项课题
2. 国家自然科学基金面上项目
3. 国家自然科学基金优秀青年科学基金项目（海外）
4. 比利时国家科学基金FNRS-CR
5. 比利时国家科学基金FNRS-ASP
6. 比利时地区政府杰出青年科学家项目
7. 欧洲研究委员会欧盟“2020地平线”框架计划重点项目
8. 比利时国家科学基金重点项目
部分代表论文：
1. Junzhu Shi, Chendong Liu, Jiaqi Liu, Yue Yan, Fengju Wang, Shenao Yan, Yucheng Xiang*, Minglu Zhou*, Yining Xu*, Lian Li*. CXCR4 Clustering Induced by Polymeric Nanothreads Impedes Cancer Cell Metastasis via PIEZO1-Mediated Mechanotransduction. Advanced Healthcare Materials, 2025, 2501072. (IF: 10)
2. Yining Xu, Cécilia Bohns Michalowski, Jackie Koehler, Tamana Darwish, Nunzio Guccio, Constanza Alcaino, Inês Domingues, Wunan Zhang, Valentina Marotti, Matthias Van Hul, Paola Paone, Melitini Koutsoviti, Ben J Boyd, Daniel J Drucker, Patrice D Cani, Frank Reimann*, Fiona M Gribble*, Ana Beloqui*. Smart control lipid-based nanocarriers for fine-tuning gut hormone secretion. Science Advances, (2024): 10 (50), eadq9909. (IF: 11.7)
3. Valentina Marotti1, Yining Xu1, Cécilia Bohns Michalowski1, Wunan Zhang, Inês Domingues, Hafsa Ameraoui, Tom G Moreels, Pieter Baatsen, Matthias Van Hul, Giulio G Muccioli, Patrice D Cani, Mireille Alhouayek, Alessio Malfanti, Ana Beloqui*. A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment. Bioactive Materials, 32 (2024) 206–221. (co-first author) (IF: 18.9)
4. Cheng Chen, Ana Beloqui*, Yining Xu*. Oral nanomedicine biointeractions in the gastrointestinal tract in health and disease. Advanced Drug Delivery Reviews, (2023): 115117. (IF: 16.1)
5. Yining Xu1, Thibaut Fourniols1, Yasmine Labrak1, Véronique Préat, Ana Beloqui*, Anne des Rieux*. Surface Modification of Lipid-Based Nanoparticles. ACS NANO, 16 (2022) 7168-7196. (IF: 17.1)
6. Yining Xu1, Neha Shrestha1, Véronique Préat*, Ana Beloqui*. An overview of in vitro, ex vivo and in vivo models for studying the transport of drugs across intestinal barriers. Advanced Drug Delivery Reviews, 175 (2021): 1137952. (IF: 17.873)
7. Yining Xu, Herlinde De Keersmaecker, Kevin Braeckmans, Stefaan De Smedt, Patrice D. Cani, Véronique Préat, Ana Beloqui*. Targeted nanoparticles towards increased L cell stimulation as a strategy to improve oral peptide delivery in incretin-based diabetes treatment. Biomaterials, 255 (2020) 120209. (IF: 15.304)
8. Yining Xu, Matthias van Hul, Francesco Suriano, Véronique Préat, Patrice D. Cani*, Ana Beloqui*. Novel strategy for oral peptide delivery in incretin-based diabetes treatment. Gut, 69 (2020) 911-919. (IF: 31.793)
9. Yining Xu, Neha Shrestha, Véronique Préat, Ana Beloqui*. Overcoming the intestinal barrier: A look into targeting approaches for improved oral drug delivery systems. Journal of Controlled Release, 322 (2020) 486-508. (IF: 11.467)
10. Yining Xu1, Yaxian Zheng1, Lei Wu, Xi Zhu, Zhirong Zhang, Yuan Huang*. A novel solid lipid nanoparticle with endosomal escaping function for oral insulin delivery. ACS Applied Materials & Interfaces, 10 (2018) 9315-9324. (IF: 8.456)
研究生部公众号
川公网安备51010702002012